Myristoleic Acid
(Synonyms: 肉豆蔻酸; 肉豆蔻油酸) 目录号 : GC11087
Myristoleic Acid一种生物活性不饱和脂肪酸，能够从肉豆蔻科植物种子中提取，或由肉豆蔻酸通过生物体内的去饱和酶生物合成。
Cas No.:544-64-9
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
Myristoleic acid is a biologically active unsaturated fatty acid that can be extracted from the seeds of plants of the Myristicaceae family or biosynthesized from myristic acid by desaturase in vivo[1, 2]. Myristoleic acid has cytotoxic effects and can induce apoptosis and necrosis of human prostate cells[3, 4]. Myristoleic acid can inhibit the biofilm formation of Propionibacterium acnes and the mixed biofilm formation of Propionibacterium acnes and Staphylococcus aureus, and regulate the expression of several biofilm-related genes, such as lipase, hyaluronan lyase, and virulence-related genes[5].
In vivo, Myristoleic acid (0.2, 2mg/kg) treated C57BL/6 mice by intraperitoneal injection for 4 days inhibited the formation of TRAP-positive osteoclasts induced by sRANKL and attenuated the increase in osteoclast surface per bone surface (OC.S/BS), osteoclasts per bone perimeter (OC/B.Pm), and eroded surface per bone surface (ES/BS) in a dose-dependent manner[6].
References:
[1] Gao B, Yu L. Bioactive Fatty Acids[J]. 2025.
[2] Liu Y, Shen N, Xin H, et al. Unsaturated fatty acids in natural edible resources, a systematic review of classification, resources, biosynthesis, biological activities and application[J]. Food Bioscience, 2023, 53: 102790.
[3] Zhou Y, Xu J, MacIsaac H J, et al. Comparative metabolomic analysis of exudates of microcystin-producing and microcystin-free Microcystis aeruginosa strains[J]. Frontiers in Microbiology, 2023, 13: 1075621.
[4] Iguchi K, Okumura N, Usui S, et al. Myristoleic acid, a cytotoxic component in the extract from Serenoa repens, induces apoptosis and necrosis in human prostatic LNCaP cells[J]. The prostate, 2001, 47(1): 59-65.
[5] Kim Y G, Lee J H, Lee J. Antibiofilm activities of fatty acids including myristoleic acid against Cutibacterium acnes via reduced cell hydrophobicity[J]. Phytomedicine, 2021, 91: 153710.
[6] Kwon J O, Jin W J, Kim B, et al. Myristoleic acid inhibits osteoclast formation and bone resorption by suppressing the RANKL activation of Src and Pyk2[J]. European journal of pharmacology, 2015, 768: 189-198.
Myristoleic Acid一种生物活性不饱和脂肪酸，能够从肉豆蔻科植物种子中提取，或由肉豆蔻酸通过生物体内的去饱和酶生物合成[1, 2]。Myristoleic Acid具有细胞毒性作用，能够诱导人前列腺细胞的凋亡和坏死[3, 4]。Myristoleic Acid能够抑制痤疮丙酸杆菌的生物膜形成以及痤疮丙酸杆菌和金黄色葡萄球菌的混合生物膜形成，并调节几种生物膜相关基因的表达，例如脂肪酶、透明质酸裂解酶和毒力相关基因[5]。
在体内，Myristoleic Acid（0.2, 2mg/kg）通过腹腔注射处理C57BL/6小鼠4天，抑制了sRANKL诱导的TRAP阳性破骨细胞的生成，并以剂量依赖性方式减弱每骨表面破骨细胞表面（OC.S/BS）、每骨周长破骨细胞（OC/B.Pm）和每骨表面侵蚀表面（ES/BS）的破骨细胞指数的增加[6]。
| Animal experiment [1]: | |
|
Animal models |
C57BL/6 mice |
|
Preparation Method |
C57BL/6 mice at 5 weeks of age were divided into 4 groups. The control group was treated with PBS every 24h for 4 days and the other groups received intraperitoneal injections of 1mg/kg soluble RANKL (sRANKL) every 24h for 4 days. 12h after the injection of sRANKL, each of two groups received 0.2mg/kg Myristoleic acid or 2mg/kg Myristoleic acid every 24h for 4 days. All mice were killed at day 4. The left femurs were analyzed by micro-computed tomography (μCT) using a SMX-90CT system (90kVp, 109mA, and 180-ms integration time). The right femurs were fixed in 4% paraformaldehyde and decalcified in 12% EDTA for 5 weeks. Decalcified femurs were dehydrated with 70% to 100% ethanol and embedded in paraffin. Histological samples sectioned to 5μm thickness were stained for TRAP or with hematoxylin and eosin (H&E). Analysis of bone histomorphometric parameters was performed by using the Osteomeasure program. |
|
Dosage form |
0.2, 2mg/kg/day; 4 days; i.p. |
|
Applications |
Co-administration of Myristoleic acid suppressed generation of TRAP-positive osteoclasts induced by sRANKL and attenuated the increases in osteoclastic indices of osteoclast surface per bone surface (OC.S/BS), osteoclasts per bone perimeter (N.OC/B.Pm) and eroded surface per bone surface (ES/BS) in a dose-dependent manner. |
|
References: |
|
| Cas No. | 544-64-9 | SDF | |
| 别名 | 肉豆蔻酸; 肉豆蔻油酸 | ||
| Canonical SMILES | OC(CCCCCCC/C=C\CCCC)=O | ||
| 分子式 | C14H26O2 | 分子量 | 226.4 |
| 溶解度 | DMF: 3 mg/ml,DMSO: 2.5 mg/ml,Ethanol: miscible,PBS (pH 7.2): 2 mg/ml | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 4.417 mL | 22.0848 mL | 44.1696 mL |
| 5 mM | 0.8834 mL | 4.417 mL | 8.8339 mL |
| 10 mM | 0.4417 mL | 2.2085 mL | 4.417 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >99.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet